Early stage ER positive, HER2 negative disease is known to have the lowest absolute benefit from chemotherapy compared to the other breast cancer subtypes,27 and multigene signatures may be useful to optimize treatment decisions.10 This evidence concerns the gene ESR1 and breast cancer.